I watched a lecture by Heather Payne (prostate oncologist at UCLH) which was sponsored by PCUK (so I hope it's OK to mention her name in this context).
Heather talked about quality of life comparison between early chemo versus early novel ADT drugs (mainly Abiraterone as it's been around the longest so we know more about it, but also Enzalutamide and Daralutamide).
This showed a quality of life dip during early chemo, which recovers afterwards, but it never gets back to the same level as those on early Abiraterone instead (and you can probably assume all the *utamide drugs are similar to Abiraterone in this respect). This was not a comparison of survival and Heather didn't compare survival of early chemo versus early novel ADT drugs, other than to say that either of these add years over the previous standard of care which was just the traditional ADT drugs (Zoladex, Prostap, Decapaptyl, or Degarelix).
Because of your young age, you are probably considering longevity as well as quality of life, and one consideration is that you will probably have chemo at least once some point, and it can be easier to handle at a lower age when you're fitter, but can have ongoing impact on quality of life. Also, as you get older (typically from around age 70), men are less likely to be healthy enough to have chemo.
I'm not recommending one way or another, but just some things to consider, and to discuss with your oncologist and maybe clinical nurse specialists too.